Product Description
Mechanisms of Action: Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Madrigal
Company Location: WEST CONSHOHOCKEN PA 19428
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified|Leukemia|Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT00276913 | P1 |
Completed |
Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified |
None |
|
NCT00088101 | P1 |
Completed |
Leukemia|Lymphoma |
None |